Search Result

Pathways Recommended:	MAPK/ERK Pathway

Results for "

cholinergic pathway

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Akt (1) Apelin Receptor (APJ) (2) Apoptosis (1) Caspase (1) Cholinesterase (ChE) (8) Isotope-Labeled Compounds (2) mAChR (5) nAChR (5) NOD-like Receptor (NLR) (1) Potassium Channel (1) Prolyl Endopeptidase (PREP) (1) Reference Standards (1) TNF Receptor (2)
By Research Areas:	Cardiovascular Disease (5) Inflammation/Immunology (3) Neurological Disease (13)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Tissue Factor Pathway Inhibitor (TFPI)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B1277

Trihexyphenidyl hydrochloride 3 Publications Verification	mAChR Cholinesterase (ChE)	Neurological Disease
Trihexyphenidyl hydrochloride is a selective and orally active M₁ muscarinic receptor antagonist with an IC₅₀ of 3.7 nM for rat cerebral cortex M1 muscarinic receptors. Trihexyphenidyl hydrochloride modulates cholinergic activity, countering acetylcholine supersensitivity in neural pathways. Trihexyphenidyl hydrochloride improves movement disorder, inhibits McN-A-343 (HY-107648)-induced pressor responses, vagally-induced bradycardia and vasodilatation. Trihexyphenidyl hydrochloride can be used for the research of Parkinson's disease. .

HY-P3162A

(Ala13)-Apelin-13 TFA	Apelin Receptor (APJ)	Cardiovascular Disease
(Ala13)-Apelin-13 TFA is a potent apelin receptors (APJ) antagonist. (Ala13)-Apelin-13 TFA inhibits gastric motility through vagal cholinergic pathway .

HY-135483A

AR-R17779 hydrochloride	nAChR	Neurological Disease
AR-R17779 hydrochloride is a potent and selective full agonist of nAChR, with K_is of 92 and 16000 nM for α7 and α4β2 subtype, respectively. AR-R17779 hydrochloride can improve learning and memory in rats. AR-R17779 hydrochloride also has anxiolytic activity. AR-R17779 hydrochloride can reduce inflammation by activating antiinflammatory cholinergic (vagal) pathways .

HY-B1277A

Trihexyphenidyl	mAChR Cholinesterase (ChE)	Cardiovascular Disease Neurological Disease
Trihexyphenidyl is a selective and orally active M₁ muscarinic receptor antagonist with an IC₅₀ of 3.7 nM for rat cerebral cortex M1 muscarinic receptors. Trihexyphenidyl modulates cholinergic activity, countering acetylcholine supersensitivity in neural pathways. Trihexyphenidyl improves movement disorder, inhibits McN-A-343 (HY-107648)-induced pressor responses, vagally-induced bradycardia and vasodilatation. Trihexyphenidyl can be used for the research of Parkinson's disease. .

HY-P3162

(Ala13)-Apelin-13	Apelin Receptor (APJ)	Cardiovascular Disease
(Ala13)-Apelin-13 is a potent apelin receptors (APJ) antagonist. (Ala13)-Apelin-13 inhibits gastric motility through vagal cholinergic pathway .

HY-155822

TZ3O	Cholinesterase (ChE) Apoptosis Caspase	Neurological Disease
TZ3O is an anticholinergic agent with neuroprotective effects. TZ3O inhibits acetylcholinesterase (AChE) activity in human plasma with an IC₅₀ of 304.5 μM. TZ3O can improve memory impairment and cognitive decline in rats in the Scopolamine (HY-N0296)-induced Alzheimer-type model. TZ3O could be used in Alzheimer’s research .

HY-P11313

Catestatin (rat) Rat chromogranin A367–387	nAChR Akt	Cardiovascular Disease
Catestatin (rat) (Rat chromogranin A367–387) is a potent, reversible, noncompetitive, and noncooperative nicotinic *cholinergic* antagonist derived from chromogranin A (A_367-387). Catestatin (rat) inhibits norepinephrine release in rat PC12 pheochromocytoma cells (IC₅₀ = 1.2 μM), and blocks desensitization of norepinephrine release (IC₅₀ = 0.62 μM). Catestatin (rat) exerts antiadrenergic effects through the endothelial PI3K-AKT-eNOS pathway in rat papillary muscles and isolated cardiomyocytes. Catestatin (rat) maintains mitochondrial membrane potential in I/R cardiomyocytes and increases phosphorylation of AKT at S473, GSK3β at S9, PLB at T17, and eNOS at S1179. Catestatin (rat) reverses desensitization of ²²Na ⁺ uptake. Catestatin (rat) can be used for the study of nicotinic cholinergic receptor regulation and catecholamine release control mechanisms .

HY-118646

NS-6740	nAChR TNF Receptor	Neurological Disease Inflammation/Immunology
NS-6740 is a partial agonist of α7 nicotinic acetylcholine receptor (α7 nAChR) with an IC₅₀ of 3 nM. NS-6740 also acts as a potent modulator of the cholinergic anti-inflammatory pathway. NS-6740 alters the signaling pattern of α7 in an ion channel-independent manner, thereby reducing synaptic function. NS-6740 induces the desensitized state of α7 nAChR. NS-6740 generates robust nAChR-mediated currents. NS-6740 reduces LPS (HY-D1056)-induced TNF-α release from microglia. NS-6740 can be used in the research of neuroinflammation and neuropathic pain .

HY-14441

ML 10302	5-HT Receptor	Neurological Disease
ML 10302 is a potent agonist 5-HT4 receptor with K_i of 1.07 nM. 5-Hydroxytryptamine (5-HT4) receptor agonists stimulate gut motility through cholinergic pathways. ML10302 induces significant prokinesia both in the small bowel and colon through activation of cholinergic pathways. ML 10302 also has the potential for the research of neurology diseases .

HY-155823

TZ4M	Cholinesterase (ChE)	Neurological Disease
TZ4M is a 2,4-thiazolidinedione (TZD)-based anti-ADV agent with neuroprotective effects. TZ4M exhibits AChE inhibition in human plasma. TZ4M improves memory and cognitive impairment in adult rats in a scopolamine (HY-N0296)-induced Alzheimer-type model .

HY-159718

NLRP3-IN-46	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-46 (Compound 3k) activates neuro-immunomodulatory cholinergic anti-inflammatory pathway, and thus inhibits NLRP3 inflammasome activation. NLRP3-IN-46 inhibits Uric acid sodium (HY-B2130A)-induced IL-1β production in THP-1 cells, and can be used in gouty arthritis research .

HY-B1277AS

Trihexyphenidyl-d5	Isotope-Labeled Compounds mAChR Cholinesterase (ChE)	Neurological Disease
Trihexyphenidyl-d₅ is deuterium labeled Trihexyphenidyl (HY-B1277A). Trihexyphenidyl is a selective and orally active M₁ muscarinic receptor antagonist with an IC₅₀ of 3.7 nM for rat cerebral cortex M1 muscarinic receptors. Trihexyphenidyl modulates cholinergic activity, countering acetylcholine supersensitivity in neural pathways. Trihexyphenidyl improves movement disorder, inhibits McN-A-343 (HY-107648)-induced pressor responses, vagally-induced bradycardia and vasodilatation. Trihexyphenidyl can be used for the research of Parkinson's disease. .

HY-B1277S

Trihexyphenidyl-d5 hydrochloride	Isotope-Labeled Compounds mAChR Cholinesterase (ChE)	Neurological Disease
Trihexyphenidyl-d₅ hydrochloride is deuterium labeled Trihexyphenidyl hydrochloride (HY-B1277). Trihexyphenidyl hydrochloride is a selective and orally active M₁ muscarinic receptor antagonist with an IC₅₀ of 3.7 nM for rat cerebral cortex M1 muscarinic receptors. Trihexyphenidyl hydrochloride modulates cholinergic activity, countering acetylcholine supersensitivity in neural pathways. Trihexyphenidyl hydrochloride improves movement disorder, inhibits McN-A-343 (HY-107648)-induced pressor responses, vagally-induced bradycardia and vasodilatation. Trihexyphenidyl hydrochloride can be used for the research of Parkinson's disease. .

HY-B1277R

Trihexyphenidyl hydrochloride (Standard)	Reference Standards mAChR Cholinesterase (ChE)	Neurological Disease
Trihexyphenidyl hydrochloride (Standard) is the analytical standard of Trihexyphenidyl hydrochloride (HY-B1277). This product is intended for research and analytical applications. Trihexyphenidyl is a selective and orally active M₁ muscarinic receptor antagonist with an IC₅₀ of 3.7 nM for rat cerebral cortex M1 muscarinic receptors. Trihexyphenidyl modulates cholinergic activity, countering acetylcholine supersensitivity in neural pathways. Trihexyphenidyl improves movement disorder, inhibits McN-A-343 (HY-107648)-induced pressor responses, vagally-induced bradycardia and vasodilatation. Trihexyphenidyl can be used for the research of Parkinson's disease. .

HY-15116

ONO 1603	Prolyl Endopeptidase (PREP)	Neurological Disease
ONO 1603, a novel prolyl endopeptidase inhibitor investigated as a potential antidementia drug, demonstrated neuroprotective and neurotrophic effects in cerebellar granule cells similar to tetrahydroaminoacridine (THA). At a concentration of 0.03 microM, ONO 1603 promoted neuronal survival, enhanced neurite outgrowth, increased m3-muscarinic acetylcholine receptor (mAChR) mRNA levels, and stimulated mAChR-mediated signaling pathways. These findings suggest that ONO 1603 shares pharmacological similarities with THA, indicating its potential as a therapeutic agent for Alzheimer's disease by enhancing cholinergic neurotransmission and neuronal function .

HY-118646A

NS-6740 hydrochloride	nAChR TNF Receptor	Neurological Disease Inflammation/Immunology
NS-6740 hydrochloride is a partial agonist of α7 nicotinic acetylcholine receptor (α7 nAChR) with an IC₅₀ of 3 nM. NS-6740 hydrochloride also acts as a potent modulator of the cholinergic anti-inflammatory pathway. NS-6740 hydrochloride alters the signaling pattern of α7 in an ion channel-independent manner, thereby reducing synaptic function. NS-6740 hydrochloride induces the desensitized state of α7 nAChR. NS-6740 hydrochloride generates robust nAChR-mediated currents. NS-6740 hydrochloride reduces LPS (HY-D1056)-induced TNF-α release from microglia. NS-6740 hydrochloride can be used in the research of neuroinflammation and neuropathic pain .

HY-N8421

Tabernanthine	Potassium Channel	Cardiovascular Disease
Tabernanthine is a negative chronotropic and negative inotropic agent that selectively acts on sinoatrial node receptors, regulating heart rhythm and myocardial contractility. Tabernanthine exhibits atropine resistance and direct non-cholinergic binding properties, acting directly on the sinoatrial node rather than relying on vagal nerve or cholinergic pathways to exert its key activity of slowing heart rate and weakening myocardial contractility. Tabernanthine is useful in cardiovascular pharmacology research, particularly in the areas of sinoatrial node function regulation, mechanisms related to bradycardia, and studies of cardiac receptor subtype differences .

HY-106901B

Asoxime dimesylate HI-6 dimesylate	Cholinesterase (ChE) nAChR	Neurological Disease
Asoxime dimesylate (HI-6 dimesylate) is an orally active thiosemicarbazone-based antidote. Asoxime dimesylate is a reversible inhibitor of AChE, and its core mechanism of action is to re-activate AChE inhibited by nerve toxins, thereby restoring the cholinergic nerve function. Asoxime dimesylate significantly restores the function of poisoned muscles without reactivating AChE. Asoxime dimesylate is an antagonist of acetylcholine receptors (AChRs), including nicotinic receptor and α7 nAChR. Asoxime dimesylate can serve as an effective immunomodulator, improving the immune effect of the nervous system .

Cat. No.	Product Name	Target	Research Area

HY-P3162A

(Ala13)-Apelin-13 TFA	Apelin Receptor (APJ)	Cardiovascular Disease
(Ala13)-Apelin-13 TFA is a potent apelin receptors (APJ) antagonist. (Ala13)-Apelin-13 TFA inhibits gastric motility through vagal cholinergic pathway .

HY-P3162

(Ala13)-Apelin-13	Apelin Receptor (APJ)	Cardiovascular Disease
(Ala13)-Apelin-13 is a potent apelin receptors (APJ) antagonist. (Ala13)-Apelin-13 inhibits gastric motility through vagal cholinergic pathway .

HY-P11313

Catestatin (rat) Rat chromogranin A367–387	nAChR Akt	Cardiovascular Disease
Catestatin (rat) (Rat chromogranin A367–387) is a potent, reversible, noncompetitive, and noncooperative nicotinic *cholinergic* antagonist derived from chromogranin A (A_367-387). Catestatin (rat) inhibits norepinephrine release in rat PC12 pheochromocytoma cells (IC₅₀ = 1.2 μM), and blocks desensitization of norepinephrine release (IC₅₀ = 0.62 μM). Catestatin (rat) exerts antiadrenergic effects through the endothelial PI3K-AKT-eNOS pathway in rat papillary muscles and isolated cardiomyocytes. Catestatin (rat) maintains mitochondrial membrane potential in I/R cardiomyocytes and increases phosphorylation of AKT at S473, GSK3β at S9, PLB at T17, and eNOS at S1179. Catestatin (rat) reverses desensitization of ²²Na ⁺ uptake. Catestatin (rat) can be used for the study of nicotinic cholinergic receptor regulation and catecholamine release control mechanisms .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N8421

Tabernanthine	Apocynaceae Structural Classification Alkaloids Plants Indole Alkaloids Tabernanthe iboga Baill. Source Classification	Potassium Channel
Tabernanthine is a negative chronotropic and negative inotropic agent that selectively acts on sinoatrial node receptors, regulating heart rhythm and myocardial contractility. Tabernanthine exhibits atropine resistance and direct non-cholinergic binding properties, acting directly on the sinoatrial node rather than relying on vagal nerve or cholinergic pathways to exert its key activity of slowing heart rate and weakening myocardial contractility. Tabernanthine is useful in cardiovascular pharmacology research, particularly in the areas of sinoatrial node function regulation, mechanisms related to bradycardia, and studies of cardiac receptor subtype differences .

Cat. No.	Product Name	Chemical Structure

HY-B1277AS

Trihexyphenidyl-d5
Trihexyphenidyl-d₅ is deuterium labeled Trihexyphenidyl (HY-B1277A). Trihexyphenidyl is a selective and orally active M₁ muscarinic receptor antagonist with an IC₅₀ of 3.7 nM for rat cerebral cortex M1 muscarinic receptors. Trihexyphenidyl modulates cholinergic activity, countering acetylcholine supersensitivity in neural pathways. Trihexyphenidyl improves movement disorder, inhibits McN-A-343 (HY-107648)-induced pressor responses, vagally-induced bradycardia and vasodilatation. Trihexyphenidyl can be used for the research of Parkinson's disease. .

Trihexyphenidyl-d5

Trihexyphenidyl-d₅ is deuterium labeled Trihexyphenidyl (HY-B1277A). Trihexyphenidyl is a selective and orally active M₁ muscarinic receptor antagonist with an IC₅₀ of 3.7 nM for rat cerebral cortex M1 muscarinic receptors. Trihexyphenidyl modulates cholinergic activity, countering acetylcholine supersensitivity in neural pathways. Trihexyphenidyl improves movement disorder, inhibits McN-A-343 (HY-107648)-induced pressor responses, vagally-induced bradycardia and vasodilatation. Trihexyphenidyl can be used for the research of Parkinson's disease. .

HY-B1277S

Trihexyphenidyl-d5 hydrochloride
Trihexyphenidyl-d₅ hydrochloride is deuterium labeled Trihexyphenidyl hydrochloride (HY-B1277). Trihexyphenidyl hydrochloride is a selective and orally active M₁ muscarinic receptor antagonist with an IC₅₀ of 3.7 nM for rat cerebral cortex M1 muscarinic receptors. Trihexyphenidyl hydrochloride modulates cholinergic activity, countering acetylcholine supersensitivity in neural pathways. Trihexyphenidyl hydrochloride improves movement disorder, inhibits McN-A-343 (HY-107648)-induced pressor responses, vagally-induced bradycardia and vasodilatation. Trihexyphenidyl hydrochloride can be used for the research of Parkinson's disease. .

Trihexyphenidyl-d5 hydrochloride

Trihexyphenidyl-d₅ hydrochloride is deuterium labeled Trihexyphenidyl hydrochloride (HY-B1277). Trihexyphenidyl hydrochloride is a selective and orally active M₁ muscarinic receptor antagonist with an IC₅₀ of 3.7 nM for rat cerebral cortex M1 muscarinic receptors. Trihexyphenidyl hydrochloride modulates cholinergic activity, countering acetylcholine supersensitivity in neural pathways. Trihexyphenidyl hydrochloride improves movement disorder, inhibits McN-A-343 (HY-107648)-induced pressor responses, vagally-induced bradycardia and vasodilatation. Trihexyphenidyl hydrochloride can be used for the research of Parkinson's disease. .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks